Skip to main content
. 2020 Jul 16;177(21):4967–4970. doi: 10.1111/bph.15157

FIGURE 1.

FIGURE 1

The potential of cannabidiol (CBD) in SARS‐CoV2 infection. Cannadibidiol recognizes several receptor targets and displays a multifaceted immunomodulatory activity that could limit the severity of SARS‐CoV2 infection: it downregulates ACE‐2 receptors, SARS‐CoV2 gateway, it can mitigate cytokines release and reduce pulmonary inflammation and fibrosis through PPARγ receptors